Amogha Tadimety, Ph.D.

Amogha is the co-founder and CEO of Nanopath. Amogha brings a technical background in ultrasensitive biomarker detection, and multifaceted experience in life science strategy consulting and venture capital. She is dedicated to commercializing disruptive technologies with the goal of improving clinical practice. Dr. Tadimety received her B.S. in Chemical and Biological Engineering from Princeton in 2014 and her Ph.D. in Engineering from Dartmouth in 2020, where she was a fellow in the prestigious Ph.D. Innovation Program.